| University of Wisconsin-Madison, Ph.D. | |
| Medicinal Chemistry |
Dr. Roger Tung, President and Chief Executive Officer of Concert Pharmaceuticals, Inc., co-founded the Company in April 2006 based on research he carried out as an independent scientist. Before Concert, Dr. Tung worked in venture-backed start-up and major pharmaceutical companies, including Vertex Pharmaceuticals Inc., where he was a founding scientist, Merck, Sharp & Dohme Research Laboratories, and The Squibb Institute for Medicinal Chemistry. At Vertex, Dr. Tung was most recently Vice President of Drug Discovery and led their drug discovery programs at its San Diego site. He co-invented and headed discovery of Vertex’s two commercial HIV protease inhibitor products, Lexiva® and Agenerase®. He also headed development of Agenerase, in collaboration with Glaxo, through FDA and EMEA approval. Dr. Tung has overseen the discovery of 14 new chemical entities which have been studied in the clinic. He has numerous publications and has been granted 40 U.S. patents.
